| INTRODUCTION
Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the 4th most common cause of cancer deaths worldwide. its anti-angiogenic activities 5, 6 or the tumor vascular normalization during a certain time period. 7 In addition, Bv improves the tumor delivery of chemotherapeutic drugs, such as topotecan and etoposide. 8, 9 Whether Bv can exert a similar effect on the behavior of fluoropyrimidine drugs in tumors remains unknown.
Since the 1950s, 5-fluorouracil (5-FU) has been the first-line therapy for CRC. 10 Due to the complex multi-step enzymatic conversion of 5-FU, its metabolism can be easily influenced by another co-administered drug. Four intracellular enzymes are key determinants in 5-FU metabolism: dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP), thymidine kinase (TK) and thymidylate synthase (TS). More than 80% of administered 5-FU is reduced to 5,6-dihydro-5-fluorouracil (5-FUH 2 ) by DPD in the liver 10, 11 to be inactivated. In tumor tissues, 5-FU could be transferred to its activated form and finally affect DNA synthesis. 5-FU is first converted to 5-fluoro-2′-deoxyuridine (FdUrd) by TP, which is overexpressed in many types of cancer. 12, 13 Then, FdUrd is phosphorylated by TK to FdUMP, which directly binds to TS and inhibits its activity on DNA synthesis. 14 In addition, uridine phosphorylase (UP), uridine kinase (UK) and orotate phosphoribosyltransferase (OPRT) can covert 5-FU to FUMP and cause RNA synthesis inhibition. The present study innovatively explored the effects of Bv on the multi-step metabolism and tumor delivery of 5-FU in CRC models.
Among the above enzymes, TP plays a dual role in cancer. As TP converts 5-FU to its active metabolite in the first step, the overexpression of TP in cell culture and xenograft models had been shown to increase sensitivity to 5-FU due to enhanced formation of FdUMP. Interestingly, in contrast to the key role in determining fluoropyrimidine response in chemotherapy, TP is also identical to the angiogenic factor platelet-derived endothelial cell growth factor (PD-ECGF) and can aid cancer angiogenesis and progression. 15 
| MATERIALS AND METHODS

| Animals and treatments
Male athymic BALB/c nude mice (9 weeks old, 18-22 g) were pur- 
| Studies of xenograft tumor growth and surgery for tumor tissues
For tumor growth studies, mice were weighed and the major axis (a) and minor axis (b) of tumors were measured daily until day 14 before and during treatment. Tumor volume (TV) was calculated using the following formula: TV (mm
. At day 15, mice were killed, and tumor xenografts were removed and weighed.
Tumor inhibition was calculated using the following formula: Inhibition rate = (1 − mean volume of treatment group/mean volume of control group) × 100%. The removed tumor was further divided into 3 pieces, and 2 pieces were rapidly frozen in drikold and stored at −80°C for drug concentration determination and molecular biological assays. Other tissues were fixed in 4% PFA for immunostaining.
| Supplementary materials and methods
Details on the measurement of 5-FU concentration and metabolism, enzyme expression and morphological changes of tumor microvessels and are provided in Appendix S1.
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| Statistical analysis
All data are presented as means ± SEM. Statistical analysis was performed using one-way ANOVA. P < 0.05 was considered to be statistically significant. found that the expression of TP was far more than that of TK and TS in tumors. Therefore, we continued to examine Bv's effect on TP enzymatic activity, and the results showed that Bv significant reduced TP activity ( Figure 3D ). Our study focused on exploring the modulatory mechanism of Bv on TP expression.
| Bevacizumab reduced tumor microvessel density and promoted vascular normalization
From previous reports, we learnt that TP is identical to PD-ECGF and contributes significantly to angiogenesis, promoting tumor devel- It is worth noting that the most researchers attribute Bv's chemosensitization effect to its impact on tumor microvessels. Bv could exert anti-angiogenesis and block the blood and nutrition supply in tumors, 18 and some papers have revealed that Bv can promote tumor vascular normalization to promote blood perfusion and drug delivery into tumor tissues. 19, 20 However, the literature contains few studies on the effects of Bv on 5-FU metabolic enzymes.
In the present study, Bv did, as expected, enhance the antitumor effect of 5-FU in a LoVo colon cancer xenograft model, accompanied by the increased 5-FU concentration in tumors (Figures 1 and   2 ). Whether these changes were due to 5-FU metabolism was not clear.
T Drug metabolism is an important procedure closely related to therapeutic effects and multidrug resistance. 21 We found that Bv on the effect of the VEGFA/VEGFR pathway on TP expression. We found that TP upregulation by Bv depended on the VEGFA/VEGFR2 pathway rather than the VEGFA/VEGFR1 pathway ( Figure 5 ). It was reported that the promoter of either TP or VEGFA contained multiple Sp1 transcription factor-binding sites. TP and VEGFA are similarly regulated by Sp1 binding sites. 31, 32 Therefore, it is understandable that VEGFA and TP may be co-expressed in some human cancers.
However, TP is also reported to be an independent prognostic factor compared to VEGFA. 33 This suggests that TP and VEGFA expression are not always required to be coordinated. It has been reported that astrocytic TP induction by IL-1β in vivo was potentiated by conditional VEGFA inactivation, but the underlying mechanism was not studied. 34 We assumed that VEGFA diminished by Bv might enhance TP expression in the feedback loop based on Sp1 activation, which was confirmed by the data in Figure 6 . This indicates that long-term Then, the promotion of angiogenesis or resistance by TP may be diminished. We offer data to better understand how Bv synergizes with 5-FU from a metabolic perspective, and this may direct future therapeutic approaches for chemotherapy.
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